Evidence map›Paper›PMID 25231626›Full record

ArticleJournal of medical microbiology2014

Monoclonal antibodies against all known variants of EspA: development of a simple diagnostic test for enteropathogenic Escherichia coli based on a key virulence factor.

Uta Praekelt, Rolf Reissbrodt, Andreas Kresse, Asalapuram Pavankumar, Krishnan Sankaran, Roger James, Mary Jesudason, Shalini Anandan, Agila Prakasam, Veeraraghavan Balaji and 8 more

Open access · hybridAbstract readEvaluation Study
In one paragraph

Article in Journal of medical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 4 countries.

Uta PraekeltDepartment of Genetics, University of Leicester, Leicester, UK.
Rolf ReissbrodtAbteilung für Infektionskrankheiten, Robert Koch Institut, Wernigerode, Germany.
Andreas KresseAbteilung für Infektionskrankheiten, Robert Koch Institut, Wernigerode, Germany.
Asalapuram PavankumarCentre for Biotechnology, Anna University, Chennai, India.
Krishnan SankaranCentre for Biotechnology, Anna University, Chennai, India.
Roger JamesDepartment of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
Mary JesudasonChristian Medical College, Vellore, India.
Shalini AnandanChristian Medical College, Vellore, India.
Agila PrakasamChristian Medical College, Vellore, India.
Veeraraghavan BalajiChristian Medical College, Vellore, India.
Shanta DuttaNational Institute of Cholera and Enteric Diseases, Kolkata, India.
Sanjucta DuttaNational Institute of Cholera and Enteric Diseases, Kolkata, India.
Thandavarayan RamamurthyNational Institute of Cholera and Enteric Diseases, Kolkata, India.
Renate FischerR-Biopharm AG, Darmstadt, Germany.
Peter SanderR-Biopharm AG, Darmstadt, Germany.
Reiner SchaumannInstitut für Medizinische Mikrobiologie, Universität Leipzig, Leipzig, Germany.
Armando NavarroDepartment of Public Health, Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
Peter WilliamsDepartment of Genetics, University of Leicester, Leicester, UK.
Christian Medical College & Hospital · INNational Institute of Cholera and Enteric Diseases · INUniversity of Leicester · GBAnna University, Chennai · INRobert Koch Institute · DELeipzig University · DEUniversidad Nacional Autónoma de México · MX

Funding

Wellcome Trust
6 · The paper itself

Abstract

Enteropathogenic Escherichia coli (EPEC) are a major cause of infant diarrhoea in developing countries and a significant public health issue in industrialized countries. Currently there are no simple tests available for the diagnosis of EPEC. Serology of O-antigens is widely used routinely in many laboratories throughout the world, even though it has been known for many years to be an unreliable indicator of EPEC virulence. We have developed a simple, low-cost immunodiagnostic test based on the EspA filament, an essential virulence factor of EPEC and the related enterohaemorrhagic E. coli (EHEC). Using recombinant proteins of the five major variants of EspA as immunogens, we raised a panel of three monoclonal antibodies in mice that detects all variants of the native target in bacterial cultures. The antibodies proved suitable for application in sandwich-type assays, including ELISA and lateral flow immunoassays (LFI). Prototypes for both assays were specific for EPEC and EHEC strains when tested against a panel of control micro-organisms. We have also developed a simple, affordable culture medium, A/E medium, which optimizes expression of EspA allowing improved sensitivity of detection compared with standard Dulbecco's modified Eagle's medium. Together these reagents form the basis of robust, informative tests for EPEC for use especially in developing countries but also for routine screening in any clinical laboratory.

Indexed as

Antibodies, MonoclonalAnimalsDiagnostic Tests, RoutineEnterohemorrhagic Escherichia coliEnteropathogenic Escherichia coliEscherichia coli InfectionsEscherichia coli ProteinsGastroenteritisHumansImmunologic TestsMice, Inbred BALB CVirulence FactorsAntibodies, MonoclonalEscherichia coli ProteinsEspA protein, E coliVirulence Factors

Identifiers

PMID25231626
PMCPMC4250835
OpenAlexW2109780650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.